Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

This study is looking for people aged between 12 and 80 years old who have severe asthma. To be considered, your asthma needs to have been diagnosed by a doctor within the last 10 years, and you should have been taking high-dose preventer inhalers (like a combination of an inhaled steroid and a long-acting bronchodilator) consistently for at least 6 months.

Doctors will also check your lung function. You'll need to show certain measurements, like your FEV1 (a measure of how much air you can forcefully breathe out in one second) is above a certain level, and that it improves after taking a bronchodilator. This helps them understand how your lungs react to medication and how severe your asthma is.

There are also some criteria about your asthma control and other medical conditions. The study team will review your full medical history to make sure taking part is safe and appropriate for you.

If you join this study, it will last for up to 72 weeks, which is about a year and three quarters. The actual treatment with tezepelumab will go on for up to 68 weeks. You'll need to visit the study clinic once every four weeks for check-ups and to receive your tezepelumab injection. At these visits, doctors will monitor your asthma symptoms, measure your lung function, and check for any side effects. You'll also likely have blood tests and answer questionnaires about your asthma. The study is divided into different stages, where doctors will gradually assess your asthma control and potentially guide you on reducing your background asthma medication, all while ensuring your safety and well-being.